Literature DB >> 1586737

Platelet activation by cross-linking HLA class I molecules and Fc receptor.

E Rubinstein1, I Urso, C Boucheix, R C Carroll.   

Abstract

The effect on platelet activation of monoclonal antibodies directed against common determinants of the HLA class I heavy chain molecule was studied. Cross-linking W6/32, an anti-HLA class I of IgG2a subclass, led to platelet activation. Two other antibodies of the same subclass did not have this effect on platelets. The lack of activity of the F(ab')2 fragments suggests that the activation signal is mediated by the platelet Fc receptor (Fc gamma RII). Indeed, except for a higher sensitivity of W6/32 to aspirin and apyrase, activations by cross-linking IV-3 (an anti-Fc gamma RII) and W6/32 are similar at the level of InsP3 formation, calcium mobilization, pH modifications, and activation of protein kinase C and myosin kinase. When HLA class I molecules and Fc gamma RII are cross-linked together, platelet activation occurs. This is not observed when a control IgG2a is substituted for W6/32 or when CD9 and Fc receptor are cross-linked together. This suggests that HLA class I molecules and Fc gamma RII synergize to activate platelets.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1586737

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  2 in total

1.  Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.

Authors:  Cunji Gao; Brian Boylan; Dan Bougie; Joan C Gill; Jessica Birenbaum; Debra K Newman; Richard H Aster; Peter J Newman
Journal:  J Clin Invest       Date:  2009-02-09       Impact factor: 14.808

2.  A subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation.

Authors:  Maaike Rijkers; Anno Saris; Sebastiaan Heidt; Arend Mulder; Leendert Porcelijn; Frans H J Claas; Ruben Bierings; Frank W G Leebeek; A J Gerard Jansen; Gestur Vidarsson; Jan Voorberg; Masja de Haas
Journal:  Haematologica       Date:  2018-06-01       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.